Bramah_N._Singh

Bramah N. Singh

Bramah N. Singh

Cardiac pharmacologist and academic (1938–2014)

Bramah N. Singh (3 March 1938 – 20 September 2014) was a cardiac pharmacologist and academic.[1][2][3]

Early life and education

Born in Fiji, he graduated in medicine from University of Otago (New Zealand) in 1963 and completed residency at Auckland Hospital, followed by a cardiology fellowship at Green Lane Hospital. In 1969, Singh was awarded a Nuffield travelling fellowship and moved to Oxford to work with Miles Vaughan Williams. There, he worked on the anti-arrhythmic properties of drugs including amiodarone.[4][5] Such work helped to refine the characteristics of Class III compounds in the developing Vaughan Williams classification.[6]

Career

Some reviews on antidysrhythmic drugs during his lifetime credited his work in developing the classification system equally with Vaughan Williams, leading to the classification sometimes being called the Singh Vaughan Williams classification.[7][8][9]

References

  1. [1]
    Champeau, Rachel. "In memoriam: Cardiologist Dr. Bramah Singh, expert on arrhythmias". UCLA Newsroom. Retrieved 21 July 2017.
  2. [2]
    Naccarelli, GV (May 2015). "Bramah N. Singh, MD, DPhil, DSc: A Tribute". Journal of Cardiovascular Pharmacology and Therapeutics. 20 (3): 342–3. doi:10.1177/1074248415574744. PMID 25736281. S2CID 37440331.
  3. [3]
    Raven, Julia (17 October 2014). "Bramah Singh, renowned UCLA cardiologist, dies at 76". Daily Bruin. Retrieved 21 July 2017.
  4. [4]
    Singh, BN; Vaughan Williams, EM (August 1970). "A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474". British Journal of Pharmacology. 39 (4): 675–87. doi:10.1111/j.1476-5381.1970.tb09893.x. PMC 1702723. PMID 5485144.
  5. [5]
    Singh, BN; Vaughan Williams, EM (August 1970). "The effect of amiodarone, a new anti-anginal drug, on cardiac muscle". British Journal of Pharmacology. 39 (4): 657–67. doi:10.1111/j.1476-5381.1970.tb09891.x. PMC 1702721. PMID 5485142.
  6. [6]
    Kloner RA (2009). "A Salute to Our Founding Editor-in-Chief Bramah N. Singh, MD, DPhil, DSc, FRCP". Journal of Cardiovascular Pharmacology and Therapeutics. 14 (3): 154–156. doi:10.1177/1074248409343182. PMID 19721129. S2CID 44733401.
  7. [7]
    Nattel, S (26 November 1993). "Comparative mechanisms of action of antiarrhythmic drugs". The American Journal of Cardiology. 72 (16): 13F–17F. doi:10.1016/0002-9149(93)90959-G. PMID 8237825.
  8. [8]
    Nattel, S (May 1991). "Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance". Drugs. 41 (5): 672–701. doi:10.2165/00003495-199141050-00002. PMID 1712704. S2CID 46975925.
  9. [9]
    Kowey, PR; Marinchak, RA; Rials, SJ; Bharucha, D (23 October 1997). "Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs". The American Journal of Cardiology. 80 (8A): 16G–23G. doi:10.1016/S0002-9149(97)00710-8. PMID 9354408.
Share this article:

This article uses material from the Wikipedia article Bramah_N._Singh, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.